This clinical trial studies genetically modified peripheral blood stem cell transplant in treating patients with HIV-associated non-Hodgkin or Hodgkin lymphoma. Giving chemotherapy before a peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy or radiation therapy is then given to prepare the bone marrow for the stem cell transplant. Laboratory-treated stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation therapy
Name: carmustine
Description: Given IVType: DrugTreatment (gene modified peripheral blood cell transplant)
Name: cytarabine
Description: Given IVType: DrugTreatment (gene modified peripheral blood cell transplant)
Name: melphalan
Description: Given IVType: DrugTreatment (gene modified peripheral blood cell transplant)
Name: etoposide
Description: Given IVType: DrugTreatment (gene modified peripheral blood cell transplant)
Name: O6-benzylguanine
Description: Given IVType: DrugTreatment (gene modified peripheral blood cell transplant)
Name: autologous hematopoietic stem cell transplantation
Description: Undergo transduced and/or non-transduced transplantType: ProcedureTreatment (gene modified peripheral blood cell transplant)
Name: peripheral blood stem cell transplantation
Description: Undergo transduced and/or non-transduced transplantType: ProcedureTreatment (gene modified peripheral blood cell transplant)
Name: laboratory biomarker analysis
Description: Correlative studiesType: OtherTreatment (gene modified peripheral blood cell transplant)
Single Group Assignment
There is one SNP
Determine the correlation of the level of O6-methylguanine- methyltransferase (MGMT) (P140K) marking with toxicity and response. --- P140K ---